Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 9/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.37 |
| ▸ | GLP1R | P43220 | 2/20 | 0.36 |
| ▸ | SCTR | P47872 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30524338 | 0.98 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30343346 | 0.96 | PSEN1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30437059 | 0.94 | REN (0.39) | OPRD1CASP3RENCTSD | |
| SCHEMBL30524340 | 0.94 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30250211 | 0.93 | OPRD1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30438040 | 0.92 | GLP1R (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL34461945 | 0.92 | REN (0.40) | OPRD1CASP3RENCTSD | |
| SCHEMBL31002038 | 0.90 | OPRM1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30384193 | 0.90 | ACE (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL34461946 | 0.90 | REN (0.39) | OPRD1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | NEULAND LABORATORIES LTD (IN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | GCG, OGDH, ABAT | PSEN1 339/4885PSEN2 447/4885APH1B 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.